- Home
- LRE vs COCP Comparison
LRE vs COCP Comparison
Compare LRE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | COCP |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 15.6M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LRE | COCP |
|---|---|---|
| Price | $1.35 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 25.3K | ★ 41.9K |
| Earning Date | 07-30-2015 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.86 |
| 52 Week High | $2.86 | $2.19 |
Technical Indicators
Market Signals| Indicator | LRE | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 53.55 |
| Support Level | $1.34 | $1.00 |
| Resistance Level | $1.43 | $1.11 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 30.87 | 54.97 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).